231 related articles for article (PubMed ID: 27264476)
21. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases.
Ruzzenente A; Bagante F; Ratti F; Beal EW; Alexandrescu S; Merath K; Makris EA; Poultsides GA; Margonis GA; Weiss MJ; Popescu I; Aldrighetti L; Guglielmi A; Pawlik TM
HPB (Oxford); 2019 Sep; 21(9):1230-1239. PubMed ID: 30792047
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
[TBL] [Abstract][Full Text] [Related]
23. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
[TBL] [Abstract][Full Text] [Related]
24. KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
Zhang Q; Peng J; Ye M; Weng W; Tan C; Ni S; Huang D; Sheng W; Wang L
Ann Surg Oncol; 2020 Apr; 27(4):1164-1173. PubMed ID: 31720935
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.
Sasaki K; Margonis GA; Andreatos N; Wilson A; Weiss M; Wolfgang C; Sergentanis TN; Polychronidis G; He J; Pawlik TM
Br J Surg; 2017 Jun; 104(7):926-935. PubMed ID: 28266705
[TBL] [Abstract][Full Text] [Related]
26. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
[TBL] [Abstract][Full Text] [Related]
27. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.
Connell LC; Boucher TM; Chou JF; Capanu M; Maldonado S; Kemeny NE
J Surg Oncol; 2017 Mar; 115(4):480-487. PubMed ID: 28008623
[TBL] [Abstract][Full Text] [Related]
28. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
29. Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.
Margonis GA; Sasaki K; Kim Y; Samaha M; Buettner S; Amini N; Antoniou E; Pawlik TM
J Gastrointest Surg; 2016 Nov; 20(11):1821-1829. PubMed ID: 27384430
[TBL] [Abstract][Full Text] [Related]
30. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
31. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
32. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
[TBL] [Abstract][Full Text] [Related]
34. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
35. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
[TBL] [Abstract][Full Text] [Related]
36. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
[TBL] [Abstract][Full Text] [Related]
37. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.
Sasaki K; Andreatos N; Margonis GA; He J; Weiss M; Johnston F; Wolfgang C; Antoniou E; Pikoulis E; Pawlik TM
J Surg Oncol; 2016 Dec; 114(7):803-809. PubMed ID: 27792291
[TBL] [Abstract][Full Text] [Related]
38. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
[TBL] [Abstract][Full Text] [Related]
39. Is complete liver resection without resection of synchronous lung metastases justified?
Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
[TBL] [Abstract][Full Text] [Related]
40. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
